COVID-19
Conditions
Interventions
COVID-19 convalescents:Nil
vaccinated healthy individuals by COVID-19 vaccine:Nil
Sponsors
Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Object 1: 285 SARS-CoV-2 convalescents Inclusion criteria: (1) Positive result of RT-qPCR test; (2) Genomic sequencing of virus is Highly homologous with the sequence of the currently known SARS-CoV-2 specimens; (3) Positive result of IgM and IgG test; (4) In the judgement of investigator, participants who are eligible to vaccination and capable of giving personal signed informed consent. Object2: 500 vaccinated individuals by COVID-19 vaccine Inclusion criteria: (1)Axillary temperature <= 37.0 degrees C; (2)Positive reslut of RT-qPCR test previouly and Negative result currently; (3)Negative result for HIV test; (4)In the judgement of investigator, participants who are eligible to vaccination and capable of giving personal signed informed consent.
Exclusion criteria
Exclusion criteria: Object 1: 285 SARS-CoV-2 convalescents Exclusion criteria: (1)Individual whose samples are not enough for relataed tests; (2)Sample information or clinical investigation is not explicit enough; (3) Individuals are not capable of giving personal signed informed consent; (4)Individuals hava contraindications to venipuncture. Object 2: 500 vaccinated individuals by COVID-19 vaccine Exclusion criteria: (1) Individuals have fever recently; (2) With history of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component of the study intervention(s); (3) Individuals with Acute diseases, severe chronic diseases or on acute onset of chronic diseases; (4) Women who are pregnant(HCG+), have family planning within 3 months or breastfeeding; (5) Individuals with uncontrolled epilepsy or other progressive neurological disorders, or a history of Guillain-Barre syndrome; (6) Immunocompromised individuals with known or suspected immunodeficiency, as determined; by history and/or laboratory/physical examination; (7) People who are known or suspected to be suffering from severe respiratory diseases, severe cardiovascular diseases, liver or kidney diseases; (8) Current use of antitumor drug or immunosuppressor; (9) Individuals with thrombocytopenia or hemorrhagic disease; (10) In the judgement of investigator, paiticipants who are not eligible to vaccination; (11) Individuals are participating other clinical trials; (12) COVID-19 convalescents with severe sequelae, eg: lung damage et al.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Levels of SARS-CoV-2-specific antibody;Neutralizing antibody of IgG/IgM/IgAtiter (NT50) to SARS-CoV-2 infection; | — |
Countries
China
Contacts
Public ContactAi-long Huang
Chongqing Medical University
Outcome results
None listed